Showing 7261-7270 of 8649 results for "".
- Théa Open Innovation and Galimedix Partner to Develop and Commercialize GAL-101 for Ophthalmic Indicationshttps://modernod.com/news/thea-open-innovation-and-galimedix-partner-to-develop-and-commercialize-gal-101-for-ophthalmic-indications/2481497/Théa Open Innovation and Galimedix Therapeutics announced that they have signed a licensing agreement in which Galimedix will grant Théa exclusive rights for the development and commercialization of GAL-101, Galimedix’s lead disease-modifying compound, for the topical and
- Survey: Employees Value Vision Care as Much as Dental, but Many are Leaving Benefits on the Tablehttps://modernod.com/news/survey-employees-value-vision-care-as-much-as-dental-but-many-are-leaving-benefits-on-the-table/2481495/A new survey conducted by The Harris Poll for XP Health finds that employees value vision care as much as dental, but many are confused about how to take advantage of it—even when they have vision benefits. According to the
- Study: Reduced Oxygen Transport to the Retina Contributing to Damage to the Fine Blood Vessels Causes Diabetic Retinopathyhttps://modernod.com/news/study-reduced-oxygen-transport-to-the-retina-owing-to-damage-to-the-fine-blood-vessels-causes-diabetic-retinopathy/2481492/Researchers in Austria have now found evidence for a previously suspected connection: reduced oxygen transport to the retina contributes to damage to the fine blood vessels, causing diabetic retinopathy. A common complication of diabetes, this retinal damage can ultimately lead to blind
- RG6501 (OpRegen) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summithttps://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-to-be-presented-at-2023-retinal-cell-and-gene-therapy-innovation-summit/2481476/Lineage Cell Therapeutics announced that results from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the
- iSTAR Medical Initiates International STAR-VI Trial for the Use of MINIject in Conjunction with Cataract Surgeryhttps://modernod.com/news/istar-medical-initiates-international-star-vi-trial-for-the-use-of-miniject-in-conjunction-with-cataract-surgery/2481466/iSTAR Medical announced that the first patients have been implanted in its STAR-VI international trial evaluating the safety and efficacy of MINIject` in conjunction with cataract surgery in patients with primary open-angle glaucoma. iSTAR Medical’s STAR-VI trial is a pr
- Real-World Experience Shows Tepezza was Effective in Treating People with Dysthyroid Optic Neuropathy (DON)https://modernod.com/news/real-world-experience-shows-tepezza-was-effective-in-treating-people-with-dysthyroid-optic-neuropathy-don/2481465/Horizon Therapeutics announced results of an analysis of real-world treatment with Tepezza in Thyroid Eye Disease (TED) patients with DON, the majority of whom had not previously responded to other treatments. DON is a complication of TED characterized by thyroid-related impairment of visual
- GenSight Reports Topline Efficacy and Safety Results at 3 Years Post-Treatment with Lumevoqhttps://modernod.com/news/gensight-reports-topline-efficacy-and-safety-results-at-3-years-post-treatment-with-lumevoq/2481464/GenSight Biologics reported topline efficacy and safety results at 3 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (lenadogene nolparvovec). The results show sustained efficacy and favorable safety for bilateral intravitreal injection of the gene
- EyePoint and Rallybio Partner to Evaluate Inhibitor of Complement Component 5 and Durasert Technology for Intraocular Delivery in GAhttps://modernod.com/news/eyepoint-and-rallybio-partner-to-evaluate-inhibitor-of-complement-component-5-and-durasert-technology-for-intraocular-delivery-in-ga/2481435/EyePoint Pharmaceuticals and Rallybio announced a research collaboration aimed at evaluating sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. The initial focus
- Glaukos Submits NDA to FDA for iDose TRhttps://modernod.com/news/glaukos-submits-nda-to-fda-for-idose-tr/2481434/Glaukos announced the submission of a new drug application (NDA) to the FDA for iDose TR, a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.&
- Study: Low Brain Pressure Could be a Risk Factor for Developing Glaucomahttps://modernod.com/news/study-low-brain-pressure-could-be-a-risk-factor-for-developing-glaucoma/2481431/An international team of researchers led by Lithuanian scientists provide additional evidence that intracranial pressure plays an important role in normal-tension glaucoma, which accounts for up to 50 percent of all glaucoma cases. A recent clinical